Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
Eleonora Russo, Giuseppe Penno, Stefano Del Prato Department of Clinical and Experimental Medicine, Section of Diabetes and Metabolic Disease, Azienda Ospedaliero Universitaria di Pisa, and University of Pisa, Pisa, Italy Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel classified ora...
Guardado en:
Autores principales: | Russo E, Penno G, Del Prato S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/48d2c4b76bb942349b9033e8f089a3d7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz B
Publicado: (2013) -
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Bo Ahrén
Publicado: (2010) -
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto M
Publicado: (2013) -
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahren B
Publicado: (2010) -
Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Radha Andukuri, et al.
Publicado: (2009)